Table 5: Key monitoring and risk mitigation strategies for sodium–glucose co-transporter-2 inhibitors⁶⁷.

Consideration	Monitoring and/or risk mitigation strategies
Genital mycotic infections	Counsel on genital hygiene (e.g. regular bathing and wearing clean undergarments)
Hypoglycaemia	Adjust background glucose-lowering agents (e.g. insulin and/or sulfonylureas) as appropriate
Volume depletion	Proactive dose reduction of diuretics in patients at high risk for hypovolaemia Hold SGLT2 inhibitors during illness
Diabetic ketoacidosis	Educate about signs/symptoms to facilitate early recognition Monitor blood or urine ketones for very high risk Institute a sick day protocol Maintain at least low-dose insulin in insulin-requiring individuals